Inhibi4on of pkc inhibits tyrosine kinases as well o

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 4nib analogs Drug Resistance •  Where might a drug resistance muta5on arise in the progression of cancer? –  Resistance muta5on can not break ATP/substrate binding or cataly5c machinery Kinase inhibitors: gefi4nib analogs drug- resistant muta5on Thr- to- Met in the binding site produces steric clash with the drug (modeled in b) Lapa4nib and Etlo4nib F O Aniline ring Aniline ring NH Cl NH 4 N O N N O HN SO2Me Quinazoline ring Lapa4nib Notes • 4- Anilinoquinazoline structures - compare gefi4nib • EGF- receptor kinase inhibitors N O Quinazoline ring Erlo4nib (Tarceva) IC50 2 nM OMe OMe Designing Selec5ve Kinase Inhibitors •  Ac5ve conforma5on of ATP binding pocket is too similar among protein kinases •  What are some alterna5ves? Designing Selec5ve Kinase Inhibitors •  Alterna5ves: –  Target inac5ve conforma5ons that might offer more selec5vity –  Target other sites where selec5vity and synergy with ac5ve site inhibitors might be achieved –  Case study: Bcr- Abl Type II Inhibitors Protein Kinase Inhibitors Notes • Type I inhibitors act on the ac4ve conforma4on of the enzyme • Type I inhibitors bind to the ATP binding site an...
View Full Document

This note was uploaded on 01/15/2014 for the course CHEM 167 taught by Professor Amaro during the Winter '13 term at UCSD.

Ask a homework question - tutors are online